Here’s a startling fact: over 815,000 Americans are currently battling end-stage renal disease (ESRD), and chronic kidney disease (CKD) affects a staggering 14% of U.S. adults. These numbers aren’t just statistics—they represent a growing crisis in kidney health that’s driving demand for dialysis and transplants. But here’s where it gets controversial: could a class of drugs called GLP-1 agonists, like Ozempic, be a game-changer in this space? And this is the part most people miss: while these drugs don’t cure CKD, they could fundamentally alter the trajectory of the disease—and the medical devices market along with it.
CKD is a silent but relentless condition, gradually eroding kidney function until patients reach ESRD, the point where dialysis or a transplant becomes a matter of survival. The 2024 United States Renal Data System (USRDS) report paints a grim picture: between 2017 and 2020, nearly 1 in 7 U.S. adults had CKD, and the ESRD population continues to climb. What’s more, these patients often face a triple threat: diabetes, heart failure, and other cardiac issues. In 2022, a shocking 59% of ESRD patients had diabetes, while 25% and 20% struggled with heart failure and other cardiac diseases, respectively.
These figures spark a critical question: Can GLP-1 receptor agonists, like semaglutide (Ozempic), significantly improve outcomes for this vulnerable group? A groundbreaking 2024 clinical trial compared semaglutide to a placebo in patients with type 2 diabetes and CKD. The results were eye-opening: patients on semaglutide experienced a slower decline in kidney function, as measured by glomerular filtration rate (eGFR), and saw an 18% reduction in major cardiovascular events. Even more striking, their risk of death from these events dropped by 20%.
In January 2025, the FDA approved Ozempic for reducing the risk of kidney failure, disease progression, and heart problems in diabetes patients with CKD. The EMA followed suit, allowing Ozempic to include kidney disease-related benefits on its label. While it’s not a cure, Ozempic can slow CKD’s march toward ESRD and slash the risk of life-threatening cardiovascular events.
But here’s the twist: by delaying—not halting—CKD progression, Ozempic could paradoxically increase the number of patients reaching ESRD, the stage where dialysis or transplants are unavoidable. This shift could fuel demand for medical devices, from human leukocyte antigen (HLA) testing for organ matching to advanced dialysis machines. Yet, the bigger question looms: If Ozempic is used early in type 2 diabetes patients, could it prevent CKD from developing in the first place? Given that one in three adults with diabetes has CKD, treating diabetes to remission with Ozempic might stop CKD before it starts.
However, the future of dialysis care in the U.S. remains uncertain. Clinical trials are still exploring GLP-1 agonists’ full potential, and budget cuts to Medicare and Medicaid could limit patient access to these life-changing treatments. Semaglutide and similar drugs slow CKD progression and reduce cardiovascular risks, but they don’t cure kidney disease. This means clinicians must prepare for a new reality: patients living longer with early-stage CKD but still eventually needing dialysis or transplants. For the medical device industry, this could translate to higher demand for dialysis equipment, HLA testing, and transplant services.
Here’s the controversial part: While broader use of GLP-1s for diabetes remission might slash new CKD cases, long-term population effects and access barriers (like insurance coverage) make it hard to predict. Clinicians and medical device companies must plan for a mixed landscape, balancing optimism with pragmatism. Will Ozempic and its counterparts revolutionize kidney care, or will they simply shift the burden? That’s the million-dollar question—and one that demands your thoughts. What do you think? Will GLP-1 agonists transform the dialysis space, or are we overlooking potential pitfalls? Share your perspective in the comments!
